State Street SPDR S&P Pharmaceuticals ETF
XPH
71 hedge funds and large institutions have $105M invested in State Street SPDR S&P Pharmaceuticals ETF in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 10 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
13% more capital invested
Capital invested by funds: $93.1M → $105M (+$12.4M)
12.37% more ownership
Funds ownership: 41.93% → 54.29% (+12%)
3% more funds holding
Funds holding: 69 → 71 (+2)
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $853K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$17M |
| 2 |
Morgan Stanley
New York
|
+$6.5M |
| 3 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$4.71M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.97M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$19.1M |
| 2 |
FFM
Fullerton Fund Management
Singapore
|
-$1.34M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.31M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$801K |
| 5 |
Jane Street
New York
|
-$553K |
XPH Hedge Fund Activity: Q2 2022 in Review
71 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2022, worth a combined $105M — up 13% from $93.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new XPH positions and 10 closed out — a net gain of 2 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was UBS Group, adding an estimated $17M. The largest seller was Goldman Sachs, cutting an estimated $19.1M.
- 71 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2022, up from 69 in Q1 2022.
- Funds reported $105M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2022, up 13% quarter-over-quarter.
- 12 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2022 and 10 closed out, a net change of +2 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2022 was UBS Group, an estimated $17M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2022 was Goldman Sachs, an estimated $19.1M sold.
Based on aggregated 13F filings for Q2 2022.